Kawamoto Terufumi, Ito Kei, Shimizuguchi Takuya, Kito Satoshi, Nihei Keiji, Sasai Keisuke, Karasawa Katsuyuki
Division of Radiation Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo 113-8677, Japan.
Department of Radiation Oncology, Graduate School of Medicine, Juntendo University, Tokyo 113-8421, Japan.
Oncol Lett. 2018 Oct;16(4):4512-4518. doi: 10.3892/ol.2018.9229. Epub 2018 Jul 30.
Due to recent advancements in diagnostic techniques, the incidence of multiple primary cancer has increased; however, synchronous cancer of the anal canal and cervix (SCACC) is rare, and no previous studies have investigated the treatment of this disease. The present study reports a case in which intensity-modulated radiotherapy (IMRT) was used to treat a 64-year-old female with SCACC, inguinal lymphadenopathy and anal pain. The patient was diagnosed with cT3N3M0 stage IIIb anal canal squamous cell carcinoma and cT1b1N0M0 stage Ib1 cervical squamous cell carcinoma, based on biopsy and imaging study data. According to the definitive treatment for advanced-stage anal canal cancer, outpatient treatment with chemoradiotherapy (CRT) using S-1 for SCACC was recommended, as the patient did not want to undergo resection of the anus. Considering the lymph node regions involved in SCACC and the necessary doses, the treatment plan was as follows: Whole pelvis and inguinal lymph node region radiation (36 Gy/20 fractions); a first booster radiation dose (9 Gy/5 fractions) for the whole pelvis; and a second booster radiation dose (14.4 Gy/8 fractions) for the primary lesions. The patient was prescribed S-1 at a dose of 60 mg/m/day twice daily on days 1-14 and 29-42. The patient experienced grade 2 diarrhea and anal mucositis, but CRT was completed without discontinuation and hospitalization. The patient exhibited a complete response and remained disease-free without any treatment-associated complications at the 6-month follow-up. In conclusion, SCACC was successfully treated with IMRT in the present case. It is important to determine the treatment strategy for synchronous cancer types, taking into consideration the tumor stage, tumor location and patient situation.
由于诊断技术的最新进展,多原发性癌症的发病率有所上升;然而,肛管和宫颈同步癌(SCACC)较为罕见,此前尚无研究对该疾病的治疗进行过调查。本研究报告了一例使用调强放射治疗(IMRT)治疗一名患有SCACC、腹股沟淋巴结病和肛门疼痛的64岁女性的病例。根据活检和影像学研究数据,该患者被诊断为cT3N3M0 IIIb期肛管鳞状细胞癌和cT1b1N0M0 Ib1期宫颈鳞状细胞癌。根据晚期肛管癌的确定性治疗方法,由于患者不想接受肛门切除术,建议对SCACC采用S-1进行门诊放化疗(CRT)。考虑到SCACC涉及的淋巴结区域和所需剂量,治疗方案如下:全盆腔和腹股沟淋巴结区域放疗(36 Gy/20次分割);全盆腔首次增敏放疗剂量(9 Gy/5次分割);原发灶第二次增敏放疗剂量(14.4 Gy/8次分割)。患者在第1 - 14天和第29 - 42天每天两次口服S-1,剂量为60 mg/m²/天。患者出现2级腹泻和肛门黏膜炎,但CRT未中断且未住院完成。患者在6个月随访时显示完全缓解,且无任何治疗相关并发症,疾病无进展。总之,本病例中IMRT成功治疗了SCACC。考虑肿瘤分期、肿瘤位置和患者情况来确定同步癌类型的治疗策略很重要。